By increasing recombinant AAV titers, this AAV enhancer can help reduce upstream manufacturing costs and lower the cost per therapeutic dose.

By following the five steps of a specialized protocol, exceptional yields and stable cell lines can be achieved in CHO cells using antibiotic selection.

Review studies that showcase the potential of the CHOgro® Expression System in early stage drug development, where high titer antibody production is crucial.

Reduced the risk of contamination caused by repeated handling of the culture during transient protein production in suspension CHO cells

AAV therapies require high quality and high titers of viral genomes per dosage, prompting the need for a more efficient AAV manufacturing method to reduce overall costs.

Explore how the development of transfection reagents and proprietary technologies for nucleic acid delivery applications is helping product developers in the cell & gene therapy space.